The role of FGFR1 in driving luminal breast tumor progression
Fibroblast Growth Factor Receptor 1 (FGFR1) has emerged as a potential driver of endocrine resistance in a subset of luminal breast cancers. Understanding the mechanisms of resistance in the context of FGFR1-dependency is vital for improved treatment stratification of FGFR1-positive breast cancers. Our current research endeavors are directed towards unraveling the intricate mechanistic underpinnings of FGFR1's impact on breast tumor progression, specifically its contribution to endocrine resistance as well as its regulatory role in innate immune sensing and subsequent induction of Type 1 interferons (IFNs). In this project, we are exploring the potential of targeting FGFR1 in luminal breast cancer cells with aberrant FGFR1 activity to inhibit tumor growth and re-sensitize resistant tumors to endocrine treatment.
Participants: Torbjørn Lien, Sushil Dhakal, Jens Henrik Norum, Serhat Gunesten